RESEARCH ARTICLE: Pharmacokinetics, Pharmacodynamics and Drug Transport and MetabolismRegio- and Isoform-Specific Glucuronidation of psoralidin (cas 18642-23-4): Evaluation of 3-O-Glucuronidation as a Functional Marker for UGT1A9
-
Add time:09/25/2019 Source:sciencedirect.com
ABSTRACTIn th is study, we aimed to determine the glucuronidation potential of psoralidin in humans and to perform validation on use of psoralidin-3-O-glucuronidation as afunctional marker for UGT1A9. Glucuronidation kinetics was determined using human liver microsomes (HLMs), human intestine microsomes (HIM), and expressed UDP-glucuronosyltransferase (UGT) enzymes. The chemical structures of metabolites were determined by liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy analyses. Validation of psoralidin-3-O-glucuronidation as a UGT1A9 marker was performed using combined approaches including reaction phenotyping, chemical inhibition, activity correlation analysis, and determination of relative activity factor (RAF). HLM and UGT1A9 generated two monoglucuronides (9-O-glucuronide and 3-O-glucuronide) from psoralidin, whereas HIM, UGT1A1, UGT1A7, and UGT1A8 generated one only (9-O-glucuronide). Formation of 3-O-glucuronide in HLM was markedly inhibited by the UGT1A9-selective inhibitors magnolol and niflumic acid. Further, psoralidin-3-O-glucuronidation was strongly correlated with propofol-glucuronidation in a group of nine individual HLMs (r = 0.978, p < 0.001). Strong correlation was also observed between psoralidin-3-O-glucuronidation and the UGT1A9 protein levels measured by Western blotting (r = 0.944, p < 0.001). Moreover, UGT1A9 was responsible for 99.6% of psoralidin-3-O-glucuronidation in HLM based on the RAF approach. In conclusion, psoralidin was subjected to efficient glucuronidation, generating one or two monoglucuronides depending on UGT isozymes. Also, psoralidin-3-O-glucuronidation was an excellent in vitro marker for UGT1A9.
We also recommend Trading Suppliers and Manufacturers of psoralidin (cas 18642-23-4). Pls Click Website Link as below: cas 18642-23-4 suppliers
Prev:Molecular and cellular pharmacologypsoralidin (cas 18642-23-4), a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts
Next:Comparison of the in vitro metabolism of psoralidin (cas 18642-23-4) among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- psoralidin (cas 18642-23-4), a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia09/28/2019
- Pharmaceutical NanotechnologyNanoencapsulation of psoralidin (cas 18642-23-4) via chitosan and Eudragit S100 for enhancement of oral bioavailability10/01/2019
- Synthesis of psoralidin (cas 18642-23-4) derivatives and their anticancer activity: first synthesis of Lespeflorin I109/27/2019
- Comparison of the in vitro metabolism of psoralidin (cas 18642-23-4) among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes09/26/2019
- Molecular and cellular pharmacologypsoralidin (cas 18642-23-4), a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts09/24/2019
- psoralidin (cas 18642-23-4) suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines09/10/2019
- The higher osteoprotective activity of psoralidin (cas 18642-23-4) in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis09/09/2019
- Original ArticleEffect and mechanism of psoralidin (cas 18642-23-4) on promoting osteogenesis and inhibiting adipogenesis09/08/2019
- ReviewMechanisms explaining the efficacy of psoralidin (cas 18642-23-4) in cancer and osteoporosis, a review09/07/2019